Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Ductal Adenocarcinoma 1Glioma 1

Interventions

Gemcitabine 2130-nm albumin-bound paclitaxel 2paricalcitol 1mitazalimab 1ivosidenib 1Tissue Banks 1Specimen Handling 1Positron Emission Tomography Computed Tomography 1Parturition 1Oxaliplatin 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Losartan 1Leucovorin 1Irinotecan 1Hydroxychloroquine 1Glucose 1Genetic Testing 1Fluorouracil 1Fecal Microbiota Transplantation 1Escitalopram 1Contrast Media 1Capecitabine 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Ductal Adenocarcinoma × Escitalopram × 1 year × Clear all
NCT05289830 2025-12-10

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

Case Comprehensive Cancer Center

Phase 2 Terminated
4 enrolled 10 charts
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡